Zentalis Pharmaceuticals Llc (ZNTL) has had the highest return since January 1, 2026 by a US stock in the Biotechnology Industry, returning 158.5%.
| ASSET | % RETURN |
|---|---|
Zentalis Pharmaceuticals Llc (ZNTL) | 158.52% |
Alumis (ALMS) | 115.86% |
Century Therapeutics (IPSC) | 110.31% |
Regencell Bioscience (RGC) | 100.14% |
Pyxis Oncology (PYXS) | 74.58% |
Erasca (ERAS) | 67.92% |
Polyrizon Ltd Ordinary Shares (PLRZ) | 66.95% |
FibroBiologics, Inc Common Stock (FBLG) | 61.21% |
Passage Bio (PASG) | 51.78% |
Monte Rosa Therapeutics (GLUE) | 50.89% |
Genprex (GNPX) | 48.57% |
Revolution Medicines (RVMD) | 45.93% |
Alpha Tau Medical (DRTS) | 41.8% |
OKYO Pharma Ltd ADR (OKYO) | 39.13% |
iBio, Inc Common Stock (IBIO) | 38.46% |
MoonLake Immunotherapeutics (MLTX) | 37.36% |
Cyclerion Therapeutics (CYCN) | 36.8% |
Agenus (AGEN) | 33.65% |
Abcellera Biologics (ABCL) | 32.16% |
Ocugen (OCGN) | 30.88% |
Biofrontera (BFRI) | 30.88% |
CG Oncology, Inc Common stock (CGON) | 30.42% |
Neurosense Therapeutics (NRSN) | 28.75% |
Skye Bioscience, Inc Common Stock (SKYE) | 28.74% |
Mereo BioPharma Group PLC ADR (MREO) | 28.23% |
